---
title: "Genflow Biosciences (LON: GENF) Shares Jump 100% After Alternative Share Placement"
publisher: "Share Talk"
author: "sharetalk"
published: "2025-10-09T08:22:25+00:00"
modified: "2025-10-09T08:22:25+00:00"
date: 2025-10-09
canonical: "https://www.share-talk.com/genflow-biosciences-lon-genf-shares-jump-100-after-alternative-share-placement/"
category: "Health"
categories: ["Health", "Healthcare", "Pharmaceutical"]
tags: ["ageing", "cell", "Dr. Eric Leire", "GENE", "Gene Therapy", "GENF", "Genflow Biosciences", "Genflow Biosciences Plc", "IPO", "laboratory", "London Stock Exchange", "Longevity", "Patent", "process", "Share Talk", "therapies", "University of Rochester"]
image: "https://i0.wp.com/www.share-talk.com/wp-content/uploads/2025/02/Genflow-Biosciences.webp?fit=1200%2C800&ssl=1"
format: "news"
language: "en-GB"
---

# Genflow Biosciences (LON: GENF) Shares Jump 100% After Alternative Share Placement

**Published:** October 9, 2025
**Author:** sharetalk
**Categories:** Health, Healthcare, Pharmaceutical
**Tags:** ageing, cell, Dr. Eric Leire, GENE, Gene Therapy, GENF, Genflow Biosciences, Genflow Biosciences Plc, IPO, laboratory, London Stock Exchange, Longevity, Patent, process, Share Talk, therapies, University of Rochester
**Featured image:** ![](https://i0.wp.com/www.share-talk.com/wp-content/uploads/2025/02/Genflow-Biosciences.webp?fit=1200%2C800&ssl=1)

---

**Genflow Biosciences Raises £440,000 Through Alternative Share Placement.**

[Genflow Biosciences Plc](https://www.investegate.co.uk/announcement/rns/genflow-biosciences--genf/update-equity-issue-and-pdmr-notification-/9159597)announced that it has **terminated** the previously announced transaction from **October 2, 2025**, and instead completed an **alternative fundraising**, raising **£440,000 before expenses**.

The funding was secured through the **allotment of 40,000,000 new ordinary shares** at **1.1 pence per share** to **Eric Leire**. Of these, **35,454,546 shares** will be transferred to a **consortium of existing shareholders**, with **Leire retaining 4,545,454 shares**.

Both the purchasers and Leire will receive **warrants on a one-for-one basis**, exercisable at **1.2 pence per share** for **24 months**.

Following admission, the company’s **issued share capital and voting rights** will total **493,547,942 ordinary shares**. Admission to the **FCA Official List** and trading on the **London Stock Exchange** is expected at around **8:00 a.m. on October 16, 2025**.

**Dr. Eric Leire, CEO of Genflow, commented:** “We would like to express our sincere gratitude to our historical shareholders for their continued confidence and commitment to Genflow’s vision. Their ongoing support reflects a shared belief in our mission.  With this additional capital, Genflow is able to deliver on our near-term objectives.”

**About Genflow Biosciences**

Founded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow’s lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Genflow’s 12-month proof-of-concept clinical trial evaluating their SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other programs planned for 2025, include a clinical trial that will explore the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver disease for which there is no effective treatments. Please visit [www.genflowbio.com](http://www.genflowbio.com/)  and follow the Company on [LinkedIn](https://www.linkedin.com/company/genflow-biosciences/?viewAsMember=true) and [X](https://x.com/genflowbio).

---

**Original URL:** https://www.share-talk.com/genflow-biosciences-lon-genf-shares-jump-100-after-alternative-share-placement/
*Created by [WP Markdown Endpoint](https://wpmarkdownendpoint.com/)*